Nyxoah

Company Overview

Snapshot

Founded in January 2008 by Robert Taub, Nyxoah operates with 51–200 employees. The company has raised $270.7 million across 10 funding rounds from 9 investors. In May 2024, Nyxoah announced the pricing of an offering on NASDAQ, signaling continued capital market activity.

Business overview

Nyxoah is a medical device company specializing in the development and commercialization of hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA). Its core technology is a battery-free, leadless, minimally invasive neurostimulator designed to deliver bilateral hypoglossal nerve stimulation. This therapy targets patients with moderate to severe OSA who have not responded to conventional positive airway pressure treatment. Nyxoah operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers and patients globally, with a significant presence in Europe.

Strategic signal

In October 2025, Nyxoah announced the first U.S. commercial patients implanted with its Genio System, leading to a rise in its shares. This milestone is a critical validation of the company's market entry strategy and product adoption in a key healthcare market, signaling strong commercial momentum and potential for significant revenue growth to investors.

Company Intelligence Q&A

What is Nyxoah's primary focus?

Nyxoah is a medical device company focused on developing and commercializing hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA).

When did Nyxoah go public on Euronext?

Nyxoah launched its Initial Public Offering on Euronext Brussels in September 2020, raising €85 million.

What was a key recent development regarding Nyxoah's U.S. market entry?

In October 2025, Nyxoah announced the first U.S. commercial patients were implanted with its Genio System, marking a significant step in its U.S. market expansion.

Has Nyxoah secured recent funding?

In October 2024, Nyxoah raised $27 million through an At-the-Market Offering to support its U.S. presence.

What was the outcome of Nyxoah's Q3 2024 earnings call?

Nyxoah SA (NYXH) reported a Q3 2024 loss but exceeded revenue estimates, with the earnings call highlighting strategic advances amidst financial challenges in November 2024.